Table 1 Engraftment of Rin1−/− bone marrow cells

From: ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1

Antibody (lineage)

Day 34

Day 105

 

Wild type (%)

Rin1−/− (%)

Wild type (%)

Rin1−/− (%)

Bone marrow

 CD19 (B cell)

18

15

26

25

 CD11b (mac/gran)

26

25

42

41

 Ter119 (erythroid)

14

16

22

27

Spleen

 CD19 (B cell)

50

52

73

72

 CD11b (mac/gran)

4

4

5

4

 CD3e CD4 (helper T)

6

4

7

15

 CD3e CD8 (cytotoxic T)

3

2

8

6

Thymus

 CD4+ CD8− (mature T)

9

9

6

10

 CD4− CD8+ (mature T)

3

3

7

6

 CD4+ CD8+ (immature T)

80

81

82

82

 CD4− CD8− (immature T)

2

2

5

3

  1. CD45.2 wild type or Rin1−/− bone marrow samples were transplanted into lethally irradiated CD45.1 mice. After 34 or 105 days, flow cytometric analysis was performed on bone marrow, spleen and thymus cell suspensions. Data are presented as the percentage of single live donor cells (CD45.2+; 7AAD excluded).
Back to article page